Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Yasmin Yu

2PUBLICATIONS

12CO-AUTHORS

Innate immunityCancer therapy (excl. chemotherapy and radiation therapy)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (2)

Sort by Publication Date:

|Mar 20, 2024

Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy.

Yasmin Yu, Madhumita Bogdan, Muhammad Zaeem Noman

|Jun 05, 2020

Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.

Muhammad Zaeem Noman, Santiago Parpal, Kris Van Moer

Pageof 1

Frequent Collaborators

2 joint publications

Bassam Janji

1 joint publications

Muhammad Zaeem Noman

1 joint publications

Santiago Parpal

1 joint publications

Malina Xiao

1 joint publications

Jenny Viklund

1 joint publications

Angelo De Milito

1 joint publications

Jessica Martinsson

1 joint publications

Guy Berchem

1 joint publications

Hikmat Al-Hashimi

1 joint publications

Andrey Alexeyenko

Frequent Collaborators

2 joint publications

Bassam Janji

1 joint publications

Muhammad Zaeem Noman

1 joint publications

Santiago Parpal

1 joint publications

Malina Xiao

Top Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on : Jan 07, 2019

Tractable <em>In Vivo</em> Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable <em>In Vivo</em> Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on : Aug 01, 2025

See more related videos

Top Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on : Jan 07, 2019

Tractable <em>In Vivo</em> Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable <em>In Vivo</em> Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on : Aug 01, 2025

See more related videos